Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS) CALGB 100104 (Alliance) Attal, Michel , Palumbo, Antonio , Holstein, Sarah ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104
Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma Holstein, Sarah A. , Jung, Sin-Ho , Richardson, Paul G. ... - - Lancet Haematol - 2017 Manuscript - Primary - Long-Term-Followup - Myeloma - CALGB-100104
Updated analysis of CALGB 100104: lenalidomide (Len) vs. placebo maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM). Holstein, Sarah A. , Owzar, Kouros , Richardson, Paul G. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Primary - Long-Term-Followup - Myeloma - CALGB-100104
Long-term follow-up of CALGB (Alliance) 100001: Autologous followed by non-myeloablative allogeneic transplant for multiple myeloma Holstein, Sarah A. , Suman, Vera J. , Owzar, Kouros , Santo, Katelyn ... - - Biol. Blood Marrow Transplant. - 2020 Manuscript - Primary - Long-Term-Followup - Myeloma - CALGB-100001
Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of GRIFFIN After 12-months of Maintenance Therapy (AFT-29) Kaufman, Jonathan L. , Laubach, Jacob , Sborov, Douglas W. ... - ASH - Blood - 2020 Abstract - Primary - Long-Term-Followup - Myeloma - AFT-29
Overall and Progression-Free Survival Adjusted for Treatment Crossover in the CALGB 100104 Study of Lenalidomide Versus Placebo Maintenance After Stem Cell Transplant for Patients With Newly Diagnosed Multiple Myeloma (Alliance) McCarthy, Philip L. , Holstein, Sarah A. , Jung, Sin-Ho ... - IMW - - 2017 Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104
CALGB/ECOG 100104 (Alliance) Study: Lenalidomide (LEN) vs Placebo (PBO) Maintenance (Maint) After Stem Cell Transplant (SCT) for Patients (Pts) With Multiple Myeloma: Overall Survival (OS) and Progression-Free Survival (PFS) Adjusted for Treatment (Tx) Crossover (XO) McCarthy, Philip L. , Holstein, Sarah A. , Jung, Sin-Ho ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104
Lenalidomide vs Placebo Maintenance After Stem Cell Transplant for Patients With Multiple Myeloma: Overall Survival and Progression-Free Survival After Adjusting for Treatment Crossover in CALGB McCarthy, Philip L. , Holstein, Sarah A. , Jung, Sin-Ho ... - EHA - Haematologica - 2017 Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis McCarthy, Philip L. , Holstein, Sarah A. , Petrucci, Maria Teresa ... - - J. Clin. Oncol - 2017 Manuscript - Secondary-not-in-original - Primary - Myeloma - CALGB-100104
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma McCarthy, Philip L. , Owzar, Kouros , Hofmeister, Craig C. ... - - N. Engl. J. Med. - 2012 Manuscript - Primary - Primary - Myeloma - CALGB-100104
Survival analysis from the CALGB trial of lenalidomide (LEN) maintenance therapy in newly diagnosed multiple myeloma (NDMM) post-autologous stem cell transplant (ASCT), adjusting for crossover (Alliance) McCarthy, Philip L. , Suman, Vera , Cooper, Miranda , Saunders, Owain ... - ASH - Blood - 2018 Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104
Analysis Of Overall Survival (OS) In The Context Of Cross-Over From Placebo To Lenalidomide And The Incidence Of Second Primary Malignancies (SPM) In The Phase III Study Of Lenalidomide Versus Placebo Maintenance Therapy Following Autologous Stem Cell Transplant (ASCT) For Multiple Myeloma (MM) CALGB (Alliance) ECOG BMT-CTN 100104 Mccarthy, P. , Owzar, K. , Hofmeister, C. , Richardson, P. ... - IMW - Clin Lymphoma Myeloma Leuk - 2013 Abstract - Secondary-not-in-original - Primary - Myeloma - CALGB-100104
Daratumumab (DARA) + Lenalidomide/Bortezomib/Dexamethasone (RVd) in African American/Black Patients (Pts) With Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of GRIFFIN Nooka, Ajay K. , Kaufman, Jonathan L. , Rodriguez, Cesar ... - SOHO - - 2020 Abstract - Secondary-not-in-original - Primary - Myeloma - AFT-05
Daratumumab + Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN AFT-29 Voorhees, Peter M. , Kaufman, Jonathan L. , Laubach, Jacob ... - IMW - - 2019 Abstract - Primary - Primary - Myeloma - AFT-29
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial Voorhees, Peter M. , Kaufman, Jonathan L. , Laubach, Jacob ... - - Blood - 2020 Manuscript - Primary - Primary - Myeloma - AFT-29
Depth of response to daratumumab (DARA), lenalidomide, bortezomib, and dexamethasone (RVD) improves over time in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): GRIFFEN study update (AFT-29) Voorhees, Peter M. , Kaufman, Jonathan L. , Laubach, Jacob ... - ASH - Blood - 2019 Abstract - Secondary - Primary - Myeloma - AFT-29
Interim safety analysis of a phase 2 randomized study of daratumumab (dara), lenalidomide (r), bortezomib (v), and dexamethasone (d; dara‐rvd) vs. rvd in patients (pts) with newly diagnosed multiple myeloma (mm) eligible for high‐dose therapy (hdt) and autologous stem cell transplantation (asct) Voorhees, Peter M. , Morris, Michael , Costa, Luciano J. ... - ASH - Blood - 2017 Abstract - Secondary - Preliminary - Myeloma - AFT-29
Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor based therapy: Phase I results. Voorhees, Peter M. , Mulkey, Flora , Hassoun, Hani ... - ASH - Blood - 2015 Abstract - Primary - Primary - Myeloma - A061202
Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN Voorhees, Peter M. , Rodriguez, Cesar , Reeves, Brandi ... - - Blood Adv - 2021 Manuscript - Secondary - Long-Term-Followup - Myeloma - AFT-29
Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara‐Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT) Voorhees, Peter M. , Rodriguez, Cesar , Reeves, Brandi ... - ASH - Blood - 2018 Abstract - Primary - Primary - Myeloma - AFT-29
Depth of Response to Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone Improves Over Time in Patients With Transplant-Eligible Newly Diagnosed Multiple Myeloma: GRIFFIN Study Update Voorhees, Peter M , Kaufman, Jonathan L , Laubach, Jacob ... - EBMT - Bone Marrow Transplantation - 2020 Abstract - Secondary - Primary - Myeloma - AFT-29